Notice of Intent: Measuring AAV9 vector DNA in mice tissue using qPCR

The National Institutes of Health is issuing a Notice of Intent to award a firm‑fixed‑price purchase order for pre‑clinical laboratory services supporting an AAV9‑based gene‑editing therapeutic study. Work includes mouse tissue histology processing, histopathology staining, AAV9 antibody screening of mouse serum, and quantitative PCR measurement of AAV9 vector DNA in mouse tissue, all with GLP‑compliant documentation. The award is intended for Charles River Laboratories Montreal ULC, but small businesses may submit capability statements for possible competition. • Services: histology processing, histopathology staining, serology (AAV9 antibody detection), qPCR analysis of vector DNA. • Requirements: GLP‑compliant documentation, demonstration of DNA‑editing efficacy and non‑toxicity. • Eligibility: Small businesses (8(a), SDVOSB, HUBZone, etc.) may submit written capability statements by the deadline.